The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south.
While some investors embrace risk, mistakes can be costly for those who aren’t prepared.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.1% in the afternoon session after the company's CEO stated that it will continue to offer cheaper, compounded versions of GLP-1 weight-loss drugs. This statement comes on the heels of Novo Nordisk's recent termination of its partnership with Hims & Hers, where it was to supply its branded weight-loss drug, Wegovy. Novo Nordisk ended the collaboration citing concerns over Hims & Hers' promotion and sale of compounded drugs.
Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after selling off to start the week. Here's a look at what you need to know.
Telehealth company Hims & Hers (HIMS) saw a 34% stock drop after Novo Nordisk (NVO) ended their relationship. Investors must decide if it's a buying opportunity or a warning sign for the industry.
On Monday, major U.S. indices ended the day in the green with the Dow Jones Industrial Average rising 0.9% to 42,581.78, and the S&P 500 gaining nearly 1% to 6,025.17.
On Stocktwits, 24-hour message volume around HIMS soared 6,717% — the fifth highest among healthcare stocks. It was the top trending ticker on the platform late Monday.
